E Fund Management Co. Ltd. Buys 877 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

E Fund Management Co. Ltd. lifted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 13.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,200 shares of the biopharmaceutical company’s stock after acquiring an additional 877 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Ultragenyx Pharmaceutical were worth $303,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Algert Global LLC grew its stake in shares of Ultragenyx Pharmaceutical by 46.9% during the 3rd quarter. Algert Global LLC now owns 73,902 shares of the biopharmaceutical company’s stock valued at $4,105,000 after acquiring an additional 23,580 shares during the period. Bamco Inc. NY bought a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $2,666,000. Principal Financial Group Inc. grew its stake in shares of Ultragenyx Pharmaceutical by 740.0% during the 3rd quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock valued at $4,802,000 after acquiring an additional 76,150 shares during the period. Cerity Partners LLC bought a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $1,773,000. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company’s stock worth $928,000 after purchasing an additional 294 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on RARE. Cantor Fitzgerald restated an “overweight” rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. HC Wainwright restated a “buy” rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Piper Sandler upped their price target on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Monday, January 13th. Canaccord Genuity Group upped their price target on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. Finally, Wedbush restated a “neutral” rating and issued a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $93.50.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE opened at $38.62 on Friday. The business’s 50 day simple moving average is $42.57 and its 200-day simple moving average is $48.69. Ultragenyx Pharmaceutical Inc. has a 1 year low of $37.02 and a 1 year high of $60.37. The stock has a market capitalization of $3.57 billion, a price-to-earnings ratio of -6.09 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $164.88 million for the quarter, compared to analysts’ expectations of $163.23 million. On average, sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CAO Theodore Alan Huizenga sold 967 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $40,710.70. Following the transaction, the chief accounting officer now owns 50,265 shares of the company’s stock, valued at $2,116,156.50. This represents a 1.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Thomas Richard Kassberg sold 6,028 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $253,778.80. Following the completion of the transaction, the executive vice president now directly owns 265,238 shares in the company, valued at $11,166,519.80. This trade represents a 2.22 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 142,858 shares of company stock worth $6,093,035. Company insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.